# Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

> **NCT01693783** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Squamous Cell Carcinoma
- Human Papillomavirus Infection
- Recurrent Cervical Carcinoma
- Stage IVA Cervical Cancer AJCC v6 and v7
- Stage IVB Cervical Cancer AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01693783
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-03
- **Primary completion:** 2021-03-18
- **Final completion:** 2021-11-24
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693783, "Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01693783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*